FDA: Delays in Resumption of Inspections
![Data Integrity Master Class with full-day pre-course session Raw Data](files/eca/userImages/training.img/Z-ECA-Raw-Data-Data-Integrity-Masterclass.jpg)
Recommendation
27-30 August 2024
Copenhagen, Denmark
including 8 Interactive Workshops
The FDA announced in its FDA Roundup of 4 January that the agency is adjusting its planned inspection activities to the developing COVID-19 pandemic and the spread of the Omicron variant. The agency has therefore temporarily postponed certain inspection activities in the hope of resuming them as soon as possible.
The FDA will continue to conduct so-called mission-critical inspections in the US and abroad, but will reassess plans to do so as needed. The agency is also postponing plans for surveillance inspections abroad, which were supposed to begin in February 2022.
In doing so, the FDA will continue its type of "remote foreign supplier verification programme activities" to maintain surveillance of food, drugs, medical devices and tobacco products. Last year, the FDA published a Guidance for Industry that addressed this issue. However, those who hoped that this would enable the FDA to carry out remote evaluations with the same or comparable significance of an on-site inspection were deceived. Even the title "Remote Interactive Evaluations" avoided the word inspection or audit. A footnote explained that these remote evaluations do not meet the legal definition of an inspection. Ultimately, such a remote evaluation serves as a supplement to an inspection. The procedure described is very similar to a virtual inspection, so "livestreaming walkthroughs of the facility" and interviews can be conducted. Following the publication of the above guidance, FDA then updated its Question and Answer document, "Manufacturing, Supply Chain, and Drug and Biological Product Inspections during COVID-19 Public Health Emergency", which explains some of the actions to be taken when the agency cannot conduct an on-site inspection of a facility.
Related GMP News
24.07.2024FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
24.07.2024FDA describes detailed CAPA Procedure in Warning Letter
17.07.2024Congressional Scrutiny on FDA's Foreign Inspection Program puts Pressure on Agency
19.06.2024More FDA Inspections again - also in the EU?
12.06.2024GMP Problems with critical Medicinal Products - what now?
15.05.2024Lack of Quality Oversight: EU Non-Compliance Report issued to Omeprazole Manufacturer